Loading...
•
Jun 30, 2021
Fulcrum Therapeutics Q2 2021 Earnings Report
Fulcrum Therapeutics reported financial results for the second quarter of 2021 and provided a business update.
Key Takeaways
Fulcrum Therapeutics reported positive interim results from its Phase 1 trial for FTX-6058 in sickle cell disease and plans to initiate enrollment in a Phase 1b clinical trial in sickle cell patients in Q4 2021. The company's cash runway extends into Q1 2023.
Reported positive interim results from Phase 1 trial of FTX-6058 for sickle cell disease, demonstrating proof of mechanism and biology.
Plans to initiate enrollment in a Phase 1b clinical trial in sickle cell patients in Q4 2021.
Reported clinical data from ReDUX4 demonstrating slowed disease progression and improved function in FSHD.
Cash runway extends into Q1 2023.
Fulcrum Therapeutics
Fulcrum Therapeutics
Forward Guidance
Fulcrum Therapeutics expects that its existing cash, cash equivalents, and marketable securities will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the first quarter of 2023.